Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 12/20 | 0.41 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.34 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6185231 | 0.89 | GPR119 (0.40) | GPR119F2RL3BCHEHRH3PPARG | |
| SCHEMBL7588285 | 0.87 | MAPT (0.45) | GPR119NR1H2NR1H3 | |
| SCHEMBL7542094 | 0.81 | HRH3 (0.39) | GPR119F2RL3HRH3 | |
| SCHEMBL6183227 | 0.79 | GPR119 (0.52) | GPR119F2RL3HRH3PPARG | |
| SCHEMBL6183250 | 0.78 | MAPT (0.44) | GPR119 | |
| SCHEMBL7586301 | 0.78 | MAPT (0.56) | — | |
| SCHEMBL6182175 | 0.77 | GPR119 (0.51) | GPR119F2RL3PPARG | |
| SCHEMBL7544949 | 0.76 | RAB9A (0.49) | — | |
| SCHEMBL6183082 | 0.75 | CTSS (0.46) | — | |
| SCHEMBL6183679 | 0.75 | GPR119 (0.43) | GPR119F2RL3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2001068645-A2 | N-CYANOMETHYLCARBOXAMIDES AND THEIR USE AS PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2001-09-20 | — | — | WO | claimed |
| WO-2001068645-A2 | N-CYANOMETHYLCARBOXAMIDES AND THEIR USE AS PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2001-09-20 | — | — | WO | disclosed |